Treatment-Resistant Depression Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome The

DelveInsight's "Treatment Resistant Depression Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of historical and forecasted epidemiology as well as Treatment-Resistant Depression therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Treatment-Resistant Depression Market Share @ Treatment-Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Treatment-Resistant Depression Market Report
• In March 2025, atai Therapeutics Inc., announced a phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
• In March 2025, COMPASS Pathways announced phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD. Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg. The study will last up to 16 weeks including a three- to ten-week Screening Period and six-week follow-up from investigational product (IP) administration. In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.
• In March 2025, Janssen Research & Development, LLC organized a study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).
• In March 2025, Janssen-Cilag Ltd. conducted a study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).
• The total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were approximately 6,409,000 cases in 2022 and are projected to increase during the forecast period (2023-2032).
• The United States contributed to the largest number of diagnosed prevalent cases of Treatment-Resistant Depression (~71%) in the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 25% and 4% of the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, respectively, in 2022.
• Among the EU4 countries, Germany accounted for the highest number of total diagnosed prevalent cases of Treatment-Resistant Depression, whereas Italy accounted for the lowest number of cases in 2022.
• DelveInsight estimates that around 512,000 cases and 1,117,000 cases of Treatment-Resistant Depression were observed in males and females, respectively, in EU4 and the UK in 2022. The cases are projected to increase during the forecast period.
• In 2022, the maximum number of cases of Treatment-Resistant Depression was found in 50-60 years, and the least number of cases were found in 18-29 years in the US.
• The leading Treatment Resistant Depression Companies such as Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
• Promising Treatment Resistant Depression Pipeline Therapies such as NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.

Stay ahead in the Treatment-Resistant Depression Therapeutics Market with DelveInsight's Strategic Report @ Treatment-Resistant Depression Market Outlook- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment-Resistant Depression Epidemiology Segmentation in the 7MM
• Total Treatment Resistant Depression Prevalent Cases
• Treatment Resistant Depression Age-specific Cases
• Treatment Resistant Depression Gender-specific Cases
• Treatment Resistant Depression Treated Cases

Download the report to understand which factors are driving Treatment-Resistant Depression Epidemiology trends @ Treatment-Resistant Depression Prevalence- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment-Resistant Depression Marketed Drugs
• SPRAVATO (esketamine): Johnson & Johnson
SPRAVATO (esketamine) is the only nasal spray treatment indicated for Treatment-Resistant Depression. It is an NMDA receptor antagonist believed to work differently by acting on a pathway in the brain that affects glutamate. It has the first new mechanism of action in decades to treat Major Depressive Disorder. In March 2019, the FDA approved SPRAVATO as an oral antidepressant in adults with Treatment-Resistant Depression. But since then, the drug has faced many challenges as the insurance companies tried to understand the treatment and how it worked.

Treatment-Resistant Depression Emerging Drugs
• MIJ821: Novartis
MIJ821 is a potent, subtype-selective NMDAr 2B receptor, the negative allosteric modulator (NAM). The product was discovered by Cadent Therapeutics to produce rapid ketamine relief to patients without ketamine like side-effects. Later, Cadent Therapeutics licensed the intellectual property for NMDA receptor compounds (MIJ821) that selectively modulate NR2B to Novartis exclusively. The drug is undergoing a Phase II proof of concept study, the detailed results of which are still awaited.

• COMP360 (Psilocybin): COMPASS Pathways
COMP360 (Psilocybin) are naturally occurring magic mushrooms consumed for their hallucinogenic effects. It has a high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous brain areas, including the cerebral cortex and thalamus. They belong to a group of drugs known as psychedelics because of the changes experienced in perception, mood, and thought.

To learn more about Treatment-Resistant Depression treatment guidelines, visit @ Treatment-Resistant Depression Treatment Market Landscape- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Treatment-Resistant Depression Drugs Market Insights
The current treatment of Treatment-Resistant Depression consists of different approaches classified into pharmacologic and nonpharmacological therapies. Pharmacologic treatment options include switching, combination, and potentiation strategizing among the commonly used antidepressant drugs. Most of the available antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), dual serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, irreversible, non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, agomelatine, and tianeptine are used to treat Treatment-Resistant Depression.

Treatment-Resistant Depression Market Outlook
Treatment-Resistant Depression is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, chronic pain, and fibromyalgia. On the other hand, the impact of physical and psychiatric illness comorbidities is much higher among Treatment-Resistant Depression patients. Some environmental factors related to Treatment-Resistant Depression are lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower level of education, and social support and work dysfunction.

Learn more about the FDA-approved drugs for Treatment-Resistant Depression @ Drugs for Treatment-Resistant Depression Treatment- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Treatment-Resistant Depression Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Treatment-Resistant Depression Companies- Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
• Treatment Resistant Depression Pipeline Therapies- NV5138, MIJ821, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others.
• Treatment-Resistant Depression Market Dynamics: Treatment-Resistant Depression Market Drivers and Barriers
• Treatment-Resistant Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Treatment-Resistant Depression Drugs in development @ Treatment-Resistant Depression Clinical Trials Assessment- https://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Treatment-Resistant Depression Report Introduction
2. Treatment Resistant Depression (TRD) Market Overview at a Glance
3. Executive Summary of Treatment-Resistant Depression (TRD)
4. Key Events
5. Treatment-Resistant Depression Disease Background and Overview
6. Treatment-Resistant Depression Treatment
7. Treatment-Resistant Depression Methodology
8. Treatment-Resistant Depression Epidemiology and Patient Population
9. Treatment-Resistant Depression Patient Journey
10. Treatment-Resistant Depression Marketed Drugs
11. Treatment-Resistant Depression Emerging Drugs
12. Treatment-Resistant Depression (TRD): Seven Major Market Analysis
13. Treatment-Resistant Depression KOL Views
14. Treatment-Resistant Depression SWOT Analysis
15. Treatment-Resistant Depression Unmet Needs
16. Reimbursement and Treatment-Resistant Depression Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.